PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study.
The deal, announced after the market close Wednesday, will bring South Plainfield, NJ-based PTC (NASDAQ: PTCT) another compound for its pipeline of rare disease drugs.
Wellesley, MA-based Censa in December reported that its drug, an oral formulation of synthetic sepiapterin, or CNSA-001, met the main goal of a Phase 2 study evaluating the drug as a potential treatment for signs and symptoms associated with phenylketonuria (PKU), a genetic condition in which the… Read more »
UNDERWRITERS AND PARTNERS
